US equities
|
NVDA
$239.67
▲+2.44%
SPCX
$169.66
▲+6.73%
MU
$1,061.29
▼-1.27%
TSLA
$380.57
▲+2.69%
SNDK
$1,694.30
▼-1.49%
MSFT
$528.81
▲+2.18%
INTC
$116.46
▼-2.41%
META
$743.78
▲+2.16%
NVDA
$239.67
▲+2.44%
SPCX
$169.66
▲+6.73%
MU
$1,061.29
▼-1.27%
TSLA
$380.57
▲+2.69%
SNDK
$1,694.30
▼-1.49%
MSFT
$528.81
▲+2.18%
INTC
$116.46
▼-2.41%
META
$743.78
▲+2.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
GeoVax Labs, Inc. - Common Stock
(NQ:
GOVX
)
0.3304
+0.0104 (+3.25%)
Delayed Quote
Updated: 3:20 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GeoVax Labs, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 13, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 13, 2026
ATLANTA, GA - February 13, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX) (the “Company”), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and...
Via
TheNewswire.com
Topics
Regulatory Compliance
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
December 18, 2025
Via
TheNewswire.com
GeoVax Highlights 2026 as a Pivotal Year for Progress
January 20, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Highlights 2026 as a Pivotal Year for Progress
January 20, 2026
Management Highlights 2026 as a Portfolio-Wide Inflection Year Driven by Regulatory De-Risking, Clinical Readouts, and Scalable Manufacturing
Via
TheNewswire.com
Friday's pre-market session: top gainers and losers
↗
January 09, 2026
Via
Chartmill
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
January 08, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement
January 08, 2026
Via
TheNewswire.com
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
January 06, 2026
Via
TheNewswire.com
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week
January 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Stay updated with the stocks that are on the move in today's after-hours session.
↗
January 02, 2026
Via
Chartmill
Unusual volume stocks are being observed in Wednesday's session.
↗
December 24, 2025
The trading volume of these stocks is deviating from the norm in today's session.
Via
Chartmill
Which stocks are moving after the closing bell on Tuesday?
↗
December 23, 2025
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Unusual volume stocks in Tuesday's session
↗
December 23, 2025
Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
Monday's after hours session: top gainers and losers
↗
December 22, 2025
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
These stocks have an unusual volume in today's session
↗
December 22, 2025
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via
Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
December 19, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Which stocks are moving on Friday?
↗
December 19, 2025
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Via
Chartmill
Which stocks are gapping on Friday?
↗
December 19, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
December 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
December 19, 2025
Via
TheNewswire.com
Topics
Regulatory Compliance
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
December 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
December 18, 2025
Via
TheNewswire.com
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
December 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
December 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Supply Chain
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
December 17, 2025
Via
TheNewswire.com
Topics
Supply Chain
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
December 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
December 16, 2025
Via
TheNewswire.com
Topics
Intellectual Property
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
December 15, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
December 15, 2025
Via
TheNewswire.com
< Previous
1
2
3
4
5
6
7
8
9
...
25
26
Next >
